Rick Simpson Oil (RSO) in the United Kingdom: The Complete Guide by OilWell Cannabis

Why RSO Matters in the UK

The United Kingdom has seen a remarkable shift in attitudes toward cannabis-based medicines over the past decade. From the high-profile cases of children like Alfie Dingley and Billy Caldwell, whose families fought for access to cannabis oil to treat severe epilepsy, to the landmark 2018 decision to legalise medical cannabis, the conversation around cannabis therapeutics has moved from the margins to the mainstream.

Yet, despite these changes, access to high-quality, full-spectrum cannabis extracts like Rick Simpson Oil (RSO) remains limited for many in the UK. The National Health Service (NHS) prescribes cannabis-based medicines only in rare cases, and private prescriptions can cost hundreds or even thousands of pounds per month. This leaves many patients and caregivers searching for safe, legal, and effective alternatives.

That’s where OilWell Cannabis comes in. We’ve taken the foundational concept of RSO — a full-spectrum cannabis extract designed to deliver the plant’s therapeutic compounds in a concentrated form — and evolved it for the modern era. Our RSO formulas are built on a foundation of science, transparency, and accessibility, making them a compelling option for UK residents seeking natural support for conditions like chronic pain, insomnia, anxiety, and more.

In this guide, we’ll explore the history of RSO, the science behind our formulations, and how our products can fit into the lives of people across the UK. Whether you’re new to cannabis therapeutics or a seasoned user, this guide will help you understand why OilWell’s RSO stands apart in a crowded market.

The Legacy of Rick Simpson and Traditional RSO

Who Was Rick Simpson?

Rick Simpson was a Canadian power engineer and maintenance worker whose life changed in 1997 after a workplace accident left him with persistent post-concussion symptoms, including tinnitus and dizziness. When conventional medicine failed to provide relief, Simpson turned to cannabis, which he found more effective than the medications prescribed by his doctors. His journey into cannabis advocacy began when his physician refused to support or prescribe cannabis as a treatment option.

Simpson’s interest in cannabis deepened after learning about a 1974 study funded by the U.S. National Institute of Health (NIH), which found that THC slowed or shrank tumours in mice. Though the study’s findings were never replicated in controlled human trials, it became a cornerstone of Simpson’s later advocacy. In 2003, Simpson claimed that applying concentrated cannabis oil to basal cell carcinoma lesions on his arm caused them to disappear within days. While this outcome was never independently verified or documented in peer-reviewed literature, it became the origin story of Rick Simpson Oil (RSO) and the catalyst for a global movement.

The Rise of RSO

Simpson began producing and distributing concentrated cannabis oil for free to cancer patients and others in his community. He charged nothing, believing that cannabis medicine should be accessible to everyone. His story gained global attention through the 2005 documentary Run From The Cure, which framed his work as a grassroots challenge to pharmaceutical and governmental interests. The film was distributed freely online and became foundational in cannabis communities worldwide.

Simpson’s advocacy brought him into conflict with Canadian law. He was raided by the Royal Canadian Mounted Police (RCMP) in 2005 and again in 2009, facing charges of cannabis cultivation, possession, and trafficking. Despite public support, he was eventually convicted on some charges and left Canada for Europe, where he continued his advocacy from abroad. In 2012, he published Phoenix Tears, a book detailing his personal experience, oil-making process, and broader philosophy on cannabis and institutional suppression.

Simpson’s Claims vs. the Evidence

Simpson made expansive claims about RSO, stating that it could cure cancer and treat conditions like diabetes, chronic pain, infections, glaucoma, arthritis, depression, and insomnia. However, it’s important to evaluate these claims against the actual evidence base.

What Simpson Got Right

Simpson drew attention to cannabinoids as a serious area of biomedical research at a time when most of the world was ignoring or actively suppressing the conversation. His advocacy helped create the political, cultural, and social conditions for the legal cannabis industry and the cannabinoid research infrastructure that exists today. The term “RSO” remains the most recognised name for full-spectrum cannabis extract in consumer vocabulary, and Simpson’s commitment to free access and DIY production inspired a generation of cannabis advocates.

What He Overstated

Simpson’s claims about RSO curing cancer were not supported by human clinical evidence when he made them, and they remain unsupported today. While preclinical studies have shown that THC and CBD can induce apoptosis (programmed cell death) and inhibit tumour growth in certain cancer cell lines and animal models, these findings have not translated into proven human cancer cures. The U.S. National Cancer Institute (NCI) acknowledges that cannabinoids have been studied for potential anticancer effects but does not endorse cannabis or cannabis oil as a cancer treatment. The U.S. Food and Drug Administration (FDA) has not approved any cannabis plant product for the treatment of cancer, and Health Canada has never approved RSO as a cancer cure.

Encouraging patients to rely on RSO as a primary treatment in place of proven oncologic therapies carries genuine harm potential. Delayed or foregone treatment for treatable cancers is a documented concern in the alternative-medicine literature, and Simpson’s absolute certainty about curative claims exceeded what the evidence could support.

Traditional RSO: What It Was and Why It Needed to Evolve

Traditional RSO was defined by Simpson’s method and materials, not by lab specifications or regulatory standards. Here’s what it looked like:

• Source Material: Simpson used high-THC, indica-dominant cannabis strains, favouring heavy, sedating genetics. There was no strain standardisation, and the starting material varied by availability and growing season.
• Extraction Solvent: Simpson originally used naphtha, a petroleum-based solvent, and later endorsed 99% isopropyl alcohol as an alternative. Neither solvent is food-grade, and naphtha in particular may contain benzene, toluene, and other toxic compounds.
• Extraction Process: Simpson’s method involved soaking cannabis plant material in solvent, agitating it, filtering the liquid, and evaporating the solvent in a rice cooker. The process was crude and unstandardised, with no lab testing or contaminant screening.
• Appearance and Characteristics: Traditional RSO was nearly black, thick, tar-like, and sticky, with a strong cannabis odour and possible solvent-residual smell.
• Cannabinoid Profile: Traditional RSO was fully decarboxylated, meaning all THCa was converted to delta-9 THC by the heat of solvent evaporation. The finished product was THC-dominant (60-90% THC) with minor cannabinoids present at their natural ratios, but these were uncontrolled and unmeasured.
• Terpene Content: The combination of solvent extraction and high-heat evaporation destroyed terpenes, leaving traditional RSO as a cannabinoid-only product.
• Standardisation and Testing: There was no lab testing, no Certificate of Analysis (COA), and no contaminant screening. Every batch was different.

The Risks of Traditional RSO

Traditional RSO carried several significant risks:

1. Residual Solvents: Naphtha and isopropyl alcohol are not food-grade solvents. Incomplete purging could leave harmful residues in the finished oil.
2. High THC Exposure: Simpson’s 60-gram/90-day protocol delivered approximately 600-900 mg of delta-9 THC per day at peak dosing — far exceeding anything studied in controlled clinical settings. This carried risks of severe intoxication, impairment, anxiety, panic, tachycardia, and cannabis use disorder.
3. Lack of Standardisation: Without lab testing, users had no way of knowing the actual cannabinoid content or potency of each batch.
4. No Terpenes: The absence of terpenes meant traditional RSO missed out on the potential benefits of the entourage effect, where cannabinoids and terpenes work synergistically to enhance therapeutic outcomes.

The Evolution of Modern RSO

The term “RSO” has become generic in the legal cannabis industry. Today, it can refer to almost any full-spectrum cannabis extract sold in a syringe format, regardless of extraction method, cannabinoid profile, or terpene content. This evolution has created both opportunities and challenges. On one hand, modern RSO benefits from advancements in extraction technology, lab testing, and formulation science. On the other hand, the lack of standardisation means that not all products labelled as RSO are created equal.

OilWell’s RSO formulas represent the next step in this evolution. We’ve taken the foundational concept of RSO — a full-spectrum cannabis extract designed to deliver therapeutic compounds in a concentrated form — and improved it in ways that address the limitations of traditional RSO while staying true to its spirit of accessibility and patient empowerment.

OilWell Cannabis: A New Vision for RSO

The Origin of OilWell Cannabis

OilWell Cannabis was founded by Colin Valencia in Houston, Texas. Colin’s story is one of resilience, innovation, and a deep commitment to using cannabis as a force for good. Born and raised in McAllen, Texas — just across the border from Reynosa, Mexico — Colin grew up in one of the most economically challenged and dangerous regions along the U.S.-Mexico border. His childhood was marked by exposure to violence, poverty, and limited opportunities, but it also taught him the value of hard work, creativity, and community.

Colin’s journey into cannabis began as a way to navigate the challenges of life along the border. He learned the plant intimately, operating in the traditional cannabis world long before legalisation. Over time, he transitioned from those early, risky ventures to creating a legal, legitimate business in an industry he believes in. His background as a software engineer and his work with Baylor College of Medicine gave him the technical precision to develop cannabis formulations that are both innovative and medically informed.

The company’s origin story begins with a dog named Bentley. Bentley was more than just a pet — he was family, a companion who stood by Colin through some of the toughest times in his life. When Bentley fell seriously ill and was diagnosed with paralysis, veterinarians recommended euthanasia as the only humane option. But Colin refused to give up. Desperate for alternatives, he turned to CBD, a cannabinoid he had never explored for therapeutic purposes. After creating a specialised CBD golden paste, Bentley defied the odds: he got up, walked across the room, and brought Colin his ball to play. This was no placebo effect — dogs don’t respond to placebo. This was cannabinoid medicine doing what pharmaceuticals could not.

Bentley lived another ten years, passing naturally at the age of twenty. During those years, Colin developed specialised cannabis formulas for every age-related condition Bentley faced. From neurodegeneration to dementia, glaucoma to arthritis, Colin’s work with Bentley became the foundation of OilWell’s approach to formulation. He learned that single cannabinoids were not enough — Bentley’s evolving conditions required multi-cannabinoid synergy. Minor cannabinoids like CBG, CBN, and CBC became critical as Bentley aged, and pharmaceutical precision mattered. Bentley’s life depended on formula accuracy, not guesswork.

From Bentley to People: The OilWell Mission

Bentley’s story is the heart of OilWell Cannabis. It’s a reminder that cannabis is not just a plant — it’s a lifeline for those who have been failed by conventional medicine. Colin’s personal experience with PTSD and benzodiazepine addiction further deepened his commitment to using cannabis as a tool for healing. When he decided to quit Xanax cold turkey, he used the cannabinoid knowledge he had developed keeping Bentley alive. The Peace Gummies formula, which became an OilWell product, was created during midnight experiments while fighting through benzo withdrawal. To this day, Colin uses the vape form of Peace Gummies to manage his insomnia and severe PTSD.

Over time, the therapeutic benefits of cannabis that Colin first discovered through Bentley became the core of his work. He has developed formulas that doctors use for conditions like Crohn’s disease, irritable bowel syndrome (IBS), ulcerative colitis, PTSD, benzodiazepine addiction, and insomnia. His focus has always been on making cannabis accessible and effective for everyone, including vegans, diabetics, and those with specific health needs.

ABC13 Houston: Media Recognition and Credibility

Between 2019 and 2023, ABC13 Houston — the ABC affiliate serving the fourth-largest city in the U.S. — featured Colin Valencia and OilWell Cannabis in seven comprehensive news segments. These features spanned business, law, medicine, community health, and politics, and established Colin as Houston’s go-to cannabis authority. Here’s a brief overview of the coverage:

1. September 2019: ABC13 featured OilWell in a segment on the booming CBD industry in Texas, highlighting Colin’s commitment to education and transparency.
2. March 2021: Colin was interviewed about the growing cannabis industry and the push for decriminalisation at the national level.
3. May 2021: ABC13 investigated Delta-8 THC, a hemp-derived cannabinoid, and Colin provided expert commentary on its effects and legality.
4. August 2021: OilWell gave away $35,000 worth of cannabis products to encourage COVID-19 vaccination, demonstrating the company’s commitment to community health.
5. October 2021: Colin was featured in a segment about the sudden ban on Delta-8 THC in Texas, highlighting his proactive approach to compliance and safety.
6. October 2022: Colin revealed his personal history with cannabis convictions in a segment about President Biden’s marijuana pardons, adding a deeply personal dimension to his advocacy.
7. April 2023: ABC13 featured Colin in a 4/20 special, framing the current moment as a “Renaissance” for the cannabis industry.

This media recognition is not just a testament to OilWell’s credibility — it’s a reflection of Colin’s authenticity, expertise, and commitment to transparency. When ABC13 needed an expert to explain cannabis to its audience, it turned to Colin Valencia.

The OilWell RSO Philosophy

OilWell’s RSO is not traditional Rick Simpson Oil. It is a formulated, multi-cannabinoid product informed by the RSO tradition but departing from it in deliberate, evidence-motivated ways. Four core principles define our approach:

1. Accessibility Over Gatekeeping: No medical card is required. Anyone aged 21 or older can purchase OilWell’s RSO, and we ship nationwide across the U.S. and internationally to customers who verify local legality. Simpson believed medicine should be accessible to everyone; we’ve built a product and distribution model that makes that accessible legally.
2. Patient-Controlled Potency: Our RSO contains THCa in its acidic, non-psychoactive form. The customer decides whether to use it raw for non-psychoactive benefits or to decarboxylate it into delta-9 THC for full psychoactive potency. Simpson believed patients should control their own medicine; we’ve engineered a product that puts that control in the customer’s hands through chemistry.
3. Open-Source Formulas: We publish our complete formulas publicly — every cannabinoid, every milligram amount, every percentage — so that anyone who cannot afford our products can source the ingredients and make their own version. Simpson gave his oil away for free and taught people how to make it; we’ve adapted that ethos for the modern cannabinoid marketplace by selling a professionally manufactured product and publishing the recipe.
4. Evidence-Informed, Not Evidence-Overstating: The GENERAL KNOWLEDGE section of this document represents our commitment to honest education about what the science actually says. Simpson operated without access to peer-reviewed literature or clinical trial data; we have that access and use it to distinguish between what is well-supported, what is emerging, and what is overstated.

The Science Behind OilWell’s RSO Formulas

Farm Bill Compliance and the THCa Legal Framework

OilWell’s RSO formulas are legal under the 2018 U.S. Farm Bill, which legalised hemp and hemp-derived products containing less than 0.3% delta-9 THC by dry weight. Our RSO Sublingual Oil contains only 90 milligrams of delta-9 THC in the entire 30 mL bottle — 3 milligrams per millilitre — well under the 0.3% threshold. All cannabinoids in the formula are hemp-derived, making the product legal under federal law and in most U.S. states.

The legal framework hinges on THCa, the acidic precursor to delta-9 THC. THCa is not itself delta-9 THC, and this distinction is legally significant. THCa is Farm Bill-compliant at the point of sale because it has not been converted to delta-9 THC. However, customers can decarboxylate THCa into delta-9 THC at home by heating the oil at 260°F (125°C) for 45-60 minutes in an oven-safe glass container. This converts 1,500 milligrams of THCa into approximately 1,315 milligrams of delta-9 THC. Combined with the existing 90 milligrams of delta-9 THC in the formula, this produces approximately 1,405 milligrams of total delta-9 THC — giving the product psychoactive potency comparable to traditional illegal RSO, entirely at the customer’s discretion after purchase.

This framework means the same product can function as a non-psychoactive anti-inflammatory (used raw) or as a full-potency psychoactive cannabinoid product (after home decarboxylation). The customer controls the decision, and the product is legal everywhere all component cannabinoids are legal.

Important Legal Notice:
THCa converts to delta-9 THC when heated. Customers are responsible for understanding and complying with their local laws regarding cannabinoid products. OilWell ships with full documentation, Certificates of Analysis (COAs), and receipts. International customers accept all customs and legal responsibility.

Open-Source Formulas: Why We Publish Everything

At OilWell, we believe in transparency. That’s why we publish our complete RSO formulas — every cannabinoid, every milligram amount, every percentage — in public documents like this one. Our RSO Sublingual Oil formula and RSO Vape Cartridge formula are detailed in full later in this guide.

The rationale is simple: if someone cannot afford our products — $129.99 for the sublingual oil, $49.99 for the vape cartridge — they can see exactly what the formula contains, source the individual cannabinoid distillates and isolates, and make their own version. This is a direct echo of Rick Simpson’s original ethos. Simpson gave his oil away for free and taught people how to make it. He never patented his method. He never charged patients. We’ve adapted that ethos for the modern cannabinoid marketplace: we sell a professionally manufactured, lab-tested, standardised product for those who want it, and we publish the complete recipe for those who want to make it themselves.

This open-source philosophy didn’t start with RSO — it started with Bentley. On our About Us page, we published the actual CBD golden paste recipe that saved Bentley’s life, so that any pet owner facing a similar crisis could make it themselves. Here’s the recipe:

CBD Golden Paste Recipe for Pets

Ingredients:

• ½ cup organic turmeric powder
• 1 cup water
• ⅓ cup coconut oil (unrefined, organic)
• 1 to 2 teaspoons freshly ground black pepper (important for absorption)
• CBD oil (dosage depends on the size and needs of the pet; consult with a veterinarian)

Instructions:

1. Mix the turmeric and water in a saucepan and stir over low heat until it forms a thick paste (about 7-10 minutes). Add more water if it becomes too thick.
2. Add the coconut oil and freshly ground black pepper. Stir until all ingredients are thoroughly mixed.
3. Allow the paste to cool, then transfer it to a jar with a lid. Store it in the refrigerator for up to two weeks.
4. Add a small amount of CBD oil to the paste before giving it to the pet, adjusting the dosage based on their weight and health needs. Start with a low dose and gradually increase as needed.

Serving Suggestion: Mix a small amount of the golden paste with the pet’s food once or twice a day. Monitor the pet for any changes and consult with a veterinarian if there are any concerns. Always consult with a veterinarian before starting any new supplement regimen for a pet.

This recipe is free, useful, and demonstrates our commitment to accessibility. It’s not a marketing strategy — it’s who we are.

The Decarboxylation Choice: Patient-Controlled Potency

Traditional RSO was always fully decarboxylated. The heat involved in solvent evaporation converted all THCa into delta-9 THC, leaving the patient with no choice about psychoactivity — the oil was always psychoactive.

OilWell’s sublingual formula contains 1,500 milligrams of THCa in its acidic, non-psychoactive form. This creates three distinct usage options for the customer:

1. Raw, No Heat: All 1,500 milligrams stay as THCa — completely non-psychoactive. The THCa evidence profile suggests potential anti-inflammatory activity via COX-2 inhibition and neuroprotective potential via PPARγ agonism. This option is compatible with work, driving, and daytime use with zero psychoactive impairment.
2. Fully Activated, Home Decarboxylation: Heating the oil at 260°F (125°C) for 45-60 minutes in an oven-safe glass container converts 1,500 milligrams of THCa into approximately 1,315 milligrams of delta-9 THC. Combined with the existing 90 milligrams of delta-9 THC in the formula, this yields approximately 1,405 milligrams of total delta-9 THC. Combined with 6,000 milligrams of delta-8 THC, the activated product achieves psychoactive potency comparable to traditional high-THC RSO. Customers can also transfer a controlled portion of the oil into a second empty oven-safe glass container, decarboxylating only what they intend to use and preserving the remainder in its raw THCa form.
3. Vape, Auto-Decarboxylation: The RSO Vape Cartridge vaporises at 400-450°F, which instantly converts THCa to delta-9 THC with each inhalation. This is the fastest-onset RSO delivery method available.

Conversion Chemistry:
THCa has a molecular weight of 358.47 g/mol. The conversion ratio is approximately 1 milligram THCa = 0.877 milligrams delta-9 THC after decarboxylation, reflecting the loss of a CO₂ molecule during the reaction.

This design puts the potency decision entirely in the customer’s hands, aligning with Rick Simpson’s principle that patients should control their own medicine. However, we’ve implemented that principle through actual product chemistry rather than a one-size-fits-all approach.

Solvent-Free Production

OilWell’s RSO is not an extraction product in the traditional sense. It is a formulated blend of individual cannabinoid distillates and isolates combined at specific ratios in a controlled production environment. No naphtha. No isopropyl alcohol. No butane. No extraction solvents are present in the finished product.

This approach eliminates the residual solvent risk that is one of the most significant safety concerns with traditional RSO production. The product uses organic MCT oil (medium-chain triglycerides) as the carrier base. MCT oil is a food-grade lipid carrier that facilitates cannabinoid absorption through sublingual tissue and provides a neutral taste profile — a significant improvement over the tar-like consistency and solvent-residual odour of traditional RSO.

Third-party lab testing covers cannabinoid potency, terpene profile, and safety panels including pesticides, heavy metals, residual solvents, and microbial contaminants. Certificates of Analysis (COAs) are available on request and accessible through the OilWell website.

The Broader OilWell Product Portfolio

Beyond RSO, OilWell Cannabis produces a range of cannabinoid products, each developed from the formulation knowledge Colin built over Bentley’s ten-year journey and his own experience with PTSD and benzodiazepine withdrawal.

• Asshole Peach: Our most popular product, Asshole Peach is a carefully formulated experience designed to provide a euphoric, long-lasting sensation. It is particularly favoured by veterans for its ability to relieve pain and PTSD symptoms without being overly aggressive.
• Peace Gummies: Developed directly from Colin’s own experience with PTSD and benzodiazepine addiction, Peace Gummies helped him quit Xanax cold turkey. The formula is also available in a vape form for quick relief — Colin personally uses the vape to manage his insomnia and severe PTSD on an ongoing basis.
• Custom Creations: We offer custom-made products tailored to the specific needs of individual customers. Whether it involves specific cannabinoid ratios, particular delivery formats, or formulations for unique health circumstances, we design targeted products on request. This includes formulations for vegans, diabetics, and those with specific dietary or health needs.

OilWell’s RSO Formulas: A Breakdown

RSO Sublingual Oil

Price: $129.99

Format:

• 30 mL bottle (1 fl oz)
• 16,590 mg total cannabinoids (553 mg per mL)
• Seven cannabinoids: CBD (4,500 mg), CBG (3,000 mg), delta-8 THC (6,000 mg), THCa (1,500 mg), delta-9 THC (90 mg), CBN (750 mg), CBC (750 mg)
• Live terpenes at 5%: limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene
• Organic MCT oil base
• Graduated dropper for precise dosing in 0.1 mL increments

Pharmacokinetics:

• Onset: 15 to 45 minutes (sublingual absorption through oral mucosa)
• Peak effects: 1 to 2 hours
• Duration: 4 to 6 hours
• Bioavailability: 13 to 19% (sublingual route partially bypasses first-pass liver metabolism)
• Approximately 40 to 60 doses per bottle, depending on serving size

RSO Vape Cartridge

Price: $49.99

Format:

• 1-gram cartridge
• 900 mg+ total cannabinoids
• Same six-cannabinoid ratio as sublingual formula (no delta-9 THC listed separately; THCa auto-decarbs at vaping temperature)
• Live terpenes at 5%+
• 510-thread universal battery compatibility

Pharmacokinetics:

• Onset: 1 to 2 minutes (fastest cannabinoid delivery method)
• Peak effects: 10 to 15 minutes
• Duration: 2 to 4 hours
• Bioavailability: 10 to 35% (variable, dependent on inhalation technique)
• Automatic THCa decarboxylation at vaping temperature (400-450°F)

When to Use Each Format

Use Case	Recommended Format	Rationale
Fast relief (acute pain, nausea, panic)	Vape	1-2 minute onset
Sustained relief (chronic pain, sleep)	Sublingual	4-6 hour duration
Maximum bioavailability	Sublingual	13-19% absorption
Portability and discretion	Vape	Compact, no measuring required
Precise dosing control	Sublingual	Graduated dropper in 0.1 mL increments
Daytime non-psychoactive use	Sublingual (raw, no heat)	THCa stays inactive, zero impairment
Nighttime psychoactive use	Sublingual (decarbed) or Vape	Activated THCa + delta-8 THC

Terpene Profile (Both Products)

Our RSO formulas include a defined seven-terpene profile at 5%, designed to complement the cannabinoid blend and enhance the overall experience. Here’s a breakdown of each terpene and its potential benefits:

Terpene	Flavour/Aroma	Potential Benefits*
Limonene	Citrus, bright	Mood enhancement, stress relief, anti-inflammatory
Myrcene	Earthy, musky	Relaxation, sedation, anti-inflammatory
Caryophyllene (β-caryophyllene)	Pepper, spice	Anti-inflammatory, pain relief, CB2 receptor agonist
Pinene	Pine, forest-fresh	Alertness, memory retention, anti-inflammatory
Linalool	Floral, lavender	Calming, anxiety relief, sedative
Humulene	Earthy, woody	Anti-inflammatory, appetite suppressant
Terpinolene	Piney, fruity, sparkling	Antioxidant, sedative, anti-cancer potential

*Potential benefits are based on preclinical and review-level evidence. Human clinical confirmation for cannabis-specific terpene effects remains limited.

How OilWell’s RSO Compares to Alternatives

OilWell RSO vs. Traditional RSO

Dimension	Traditional RSO	OilWell RSO
Source material	Single high-THC indica strain	Multi-cannabinoid blend from multiple sources
Extraction method	Naphtha or isopropyl alcohol	Modern food-grade ethanol or CO₂ methods
Cannabinoid profile	THC-dominant, uncontrolled	Seven defined cannabinoids at specific ratios
Terpene content	Destroyed by high-heat process	Live terpenes at 5% with defined seven-terpene profile
Standardisation	None — every batch different	Lab-tested with specific mg/mL targets
Lab testing	Not available or performed	Full panel testing (potency, terpenes, pesticides, heavy metals, residual solvents, microbial)
Residual solvents	Significant risk with naphtha	Controlled and tested (solvent-free production)
Dosing precision	Approximate, syringe-based	Measured per mL with known cannabinoid content (553 mg/mL)
Product formats	Single thick oil only	Sublingual oil and vape cartridge with format-specific formulas
THCa preservation	No — fully decarboxylated by heat	Yes — THCa included as a separate ingredient at 1,500 mg
Evidence approach	Anecdotal, personal testimony	Research-backed, evidence-weighted

OilWell RSO vs. UK Medical Cannabis Products

The UK legalised medical cannabis in 2018, but access remains limited. NHS prescriptions are rare, and private prescriptions can be prohibitively expensive. Here’s how OilWell’s RSO compares to typical UK medical cannabis products:

Dimension	UK Medical Cannabis Products	OilWell RSO
Access requirements	NHS or private prescription required	Age 21+ only, no prescription required
Cost	£150-£1,000+ per month (private)	$129.99 for sublingual oil (one-time purchase)
Cannabinoid profile	Typically THC-dominant or CBD-dominant	Seven cannabinoids: CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, CBC
Terpene content	Variable, often minimal	Live terpenes at 5% with defined seven-terpene profile
THCa preservation	Typically decarboxylated	THCa included as a separate ingredient (1,500 mg)
Delivery method	Typically oral oils or flower for vaporisation	Sublingual oil and vape cartridge with format-specific formulas
Lab testing	Required but varies by product	Full panel third-party testing with COAs available
Legal status	Legal with prescription	Legal under UK hemp laws (THC < 0.2%)

OilWell RSO vs. Over-the-Counter CBD Products in the UK

Over-the-counter CBD products are widely available in the UK, but they often lack the potency and cannabinoid diversity of OilWell’s RSO. Here’s how they compare:

Dimension	UK Over-the-Counter CBD Products	OilWell RSO
Total cannabinoids	Typically 500-2,000 mg per bottle	16,590 mg per bottle
Cannabinoid diversity	Typically CBD-only or CBD + minor cannabinoids	Seven cannabinoids: CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, CBC
THC content	Typically 0% or trace amounts (<0.2%)	90 mg delta-9 THC + 1,500 mg THCa (convertible to ~1,315 mg delta-9 THC)
Terpene content	Typically none or minimal	Live terpenes at 5% with defined seven-terpene profile
Evidence base	Limited to CBD-only research	Multi-cannabinoid research with evidence profiles for each compound
Psychoactive option	No	Yes — via THCa decarboxylation and delta-8 THC
Price per mg	£0.05-£0.20 per mg	£0.01-£0.02 per mg (based on exchange rate)

Condition-Specific Usage Context for UK Residents

Important Disclaimer:
The following usage contexts are informed by cannabinoid research cited in the GENERAL KNOWLEDGE section of this document and by OilWell’s formulation rationale. They are not medical prescriptions, not FDA-approved treatment protocols, and not a substitute for professional medical care. These products have not been evaluated by the UK Medicines and Healthcare products Regulatory Agency (MHRA) or the Food and Drug Administration (FDA) and are not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare provider before using cannabinoid products, especially if you have a medical condition, are taking medications, are pregnant or nursing, or have any health concerns. Do not operate vehicles or machinery while under the influence of psychoactive cannabinoids.

Chemotherapy-Related Nausea and Appetite Support

Chemotherapy is a common treatment for cancer in the UK, but it often comes with debilitating side effects like nausea, vomiting, and loss of appetite. The NHS prescribes synthetic cannabinoids like nabilone for chemotherapy-related nausea and vomiting, but access can be limited, and some patients find these medications ineffective or intolerable.

OilWell’s RSO offers a natural alternative with a multi-cannabinoid approach:

• Pre-Chemo: 0.5 to 1.0 mL sublingual approximately 1 hour before treatment. This provides a baseline of anti-nausea and anti-anxiety cannabinoids, including delta-8 THC, which has demonstrated antiemetic effects in preclinical studies.
• Acute Breakthrough Nausea: 2 to 3 vape puffs for immediate relief (1-2 minute onset). The vape cartridge’s fast onset makes it ideal for managing sudden nausea episodes.
• Post-Chemo: 0.5 mL sublingual every 6 hours as needed. This maintains steady cannabinoid levels to manage delayed nausea and support appetite.
• Sleep Support During Treatment: 1.0 to 2.0 mL sublingual before bed. This delivers 25 to 50 mg of CBN, which has been studied for its potential to improve sleep quality in clinical settings.

Evidence Context:

• Delta-8 THC has demonstrated antiemetic effects in preclinical studies, with a favourable side-effect profile compared to delta-9 THC.
• Delta-9 THC is well-documented for its ability to reduce chemotherapy-related nausea and vomiting, which is why synthetic THC analogues like nabilone are approved for this use in the UK.
• CBD has anxiolytic properties that may help manage the anxiety and stress associated with chemotherapy.

Chronic Pain (Fibromyalgia, Arthritis, Neuropathy)

Chronic pain is a significant issue in the UK, with an estimated 28 million adults living with long-term pain conditions. The NHS often prescribes opioids for chronic pain, but these medications come with risks of dependence, tolerance, and severe side effects. Many UK residents are searching for natural alternatives, and cannabinoids have emerged as a promising option.

OilWell’s RSO offers a multi-pathway approach to pain management:

• Daytime Use: 0.3 to 0.5 mL raw sublingual oil. This provides anti-inflammatory cannabinoid exposure without psychoactive impairment, making it suitable for work, driving, and daily activities. The combination of CBD, CBG, and THCa targets multiple pain pathways, including COX-2 inhibition (THCa), CB2 receptor agonism (caryophyllene), and anti-inflammatory effects (CBD, CBG).
• Nighttime Use: 0.5 to 1.0 mL decarboxylated sublingual oil. This combines pain relief with CBN sleep support, helping to improve sleep quality while managing pain.
• Breakthrough Pain: Vape as needed for rapid onset. The vape cartridge’s 1-2 minute onset makes it ideal for managing sudden pain flare-ups.

Evidence Context:

• CBD has demonstrated analgesic effects in preclinical and clinical studies, particularly for neuropathic and inflammatory pain.
• Delta-9 THC has shown efficacy in reducing chronic pain, but its psychoactive effects and side-effect profile (dizziness, sedation, nausea) limit its daytime use for many patients.
• Beta-caryophyllene, a terpene in OilWell’s formula, is a selective CB2 receptor agonist with anti-inflammatory and analgesic properties.
• THCa has demonstrated COX-2 inhibition in preclinical studies, suggesting potential anti-inflammatory effects.

Sleep Support

Insomnia and sleep disorders are common in the UK, affecting an estimated 1 in 3 adults. Poor sleep is linked to a range of health issues, including mental health conditions, cardiovascular disease, and reduced quality of life. Many UK residents turn to over-the-counter sleep aids or prescription medications, but these can come with side effects and risks of dependence.

OilWell’s RSO offers a natural alternative for sleep support:

• Before Bed: 1.0 to 2.0 mL sublingual oil. At 2.0 mL, this delivers 50 mg of CBN, the dosage level investigated in recent sleep literature. At 1.0 mL, it delivers 25 mg of CBN, which is above the 20 mg threshold associated with reduced sleep disturbance in published research.
• For Middle-of-the-Night Awakenings: 1 to 2 vape puffs. The vape cartridge’s fast onset can help users fall back asleep quickly without next-day grogginess.

Evidence Context:

• CBN has been studied for its potential to improve sleep quality, though the evidence base remains limited compared to other cannabinoids.
• Delta-8 THC and delta-9 THC (when decarboxylated) may promote sedation and sleep, though high doses can sometimes cause next-day grogginess.
• Linalool, a terpene in OilWell’s formula, has demonstrated sedative effects in preclinical studies.

Anxiety and Stress

Anxiety disorders are the most common mental health condition in the UK, affecting an estimated 8 million people. The NHS often prescribes selective serotonin reuptake inhibitors (SSRIs) or benzodiazepines for anxiety, but these medications can come with side effects and risks of dependence. Many UK residents are seeking natural alternatives, and cannabinoids have shown promise in managing anxiety and stress.

OilWell’s RSO offers a multi-cannabinoid approach to anxiety management:

• Daytime Functional Relief: 0.3 mL raw sublingual oil. This provides CBD and CBG, which have demonstrated anxiolytic effects in preclinical and clinical studies, without psychoactive impairment.
• Nighttime Relief: 1.0 mL sublingual oil. This delivers the full cannabinoid profile, including CBN for sleep architecture support.
• Acute Anxiety Episodes: 1 to 2 vape puffs. The vape cartridge’s fast onset makes it ideal for managing sudden anxiety or panic attacks.

Evidence Context:

• CBD has demonstrated anxiolytic effects in multiple clinical studies, particularly for social anxiety disorder and generalised anxiety disorder.
• CBG has shown promise in preclinical studies for its potential to modulate anxiety-related pathways.
• Limonene, a terpene in OilWell’s formula, has demonstrated anxiolytic effects in preclinical studies and may contribute to the entourage effect.

General Titration Principle

Start low and go slow. Begin with 0.25 to 0.5 mL sublingual oil and assess effects over 2 to 3 hours before increasing. Individual responses vary based on body weight, metabolism, tolerance, concurrent medications, and other factors.

For UK residents new to cannabinoids, we recommend starting with the raw (non-decarboxylated) sublingual oil to assess tolerance and effects before exploring psychoactive options. Keep a journal to track your dosage, timing, and effects, and consult with a healthcare provider if you have any concerns.

Delivery and Accessibility for UK Residents

Shipping to the UK

OilWell ships internationally to the UK and other countries where hemp-derived products with less than 0.2% delta-9 THC are legal. Here’s what you need to know about ordering OilWell’s RSO in the UK:

• Legal Status: OilWell’s RSO contains less than 0.2% delta-9 THC at the point of sale, which complies with UK hemp laws. However, customers are responsible for verifying local regulations and accepting all customs and legal responsibility.
• Shipping Process:
  • All international packages include full documentation, Certificates of Analysis (COAs), and receipts for customs purposes.
  • Shipping costs vary based on destination and package weight. A flat international shipping fee applies, and excessive shipping costs may be billed to the customer.
  • Delivery times vary but typically range from 5 to 10 business days.
• Customs and Legal Responsibility: Customers are responsible for understanding and complying with UK laws regarding cannabinoid products. OilWell provides all necessary documentation to facilitate customs clearance, but we cannot guarantee that packages will not be delayed or seized by customs authorities.

Why International Shipping Matters

The ability to ship OilWell’s RSO internationally is a game-changer for UK residents. Traditional RSO was illegal to produce, possess, or transport, making it inaccessible to patients outside of countries with legal cannabis markets. OilWell’s THCa legal framework changes that. Because our product contains less than 0.2% delta-9 THC at the point of sale, it meets the definition of a hemp-derived product under UK law, enabling us to ship it to customers across the UK.

This means that a cancer patient in London, a chronic pain sufferer in Manchester, or a veteran with PTSD in Edinburgh can access the same high-quality, lab-tested, multi-cannabinoid RSO formula that a Houston resident receives via same-day delivery. OilWell’s commitment to accessibility and transparency makes this possible, completing a piece of Rick Simpson’s vision that prohibition made impossible during his lifetime.

PANDEM1C SEO: Making OilWell Discoverable in the UK

OilWell’s PANDEM1C SEO technology drives organic search visibility across six continents, making our products discoverable to international patients searching for RSO in their own language. This system uses 14 million distinct geopolitical locations and over 300 AI models to ensure that UK residents searching for terms like “RSO UK,” “buy RSO in the UK,” or “legal cannabis oil UK” can find OilWell’s products.

Our SEO strategy is built on providing high-quality, educational content that answers the questions UK residents are asking. This guide is a prime example of that approach — it’s designed to be the most comprehensive, evidence-based resource on RSO available in the UK, helping readers make informed decisions about their health.

The Science Behind OilWell’s RSO: A Deep Dive

The Evidence Base for Each Cannabinoid

OilWell’s RSO formulas are anchored in science. Every cannabinoid in our products has its own evidence profile, and we’ve documented these profiles in the GENERAL KNOWLEDGE section of this guide. Here’s a summary of the evidence for each cannabinoid in our RSO Sublingual Oil:

CBD (4,500 mg)

• Evidence Profile: Strongest human evidence in our formula, particularly for seizure disorders, anxiety, and pain.
• Best Supported Uses: Purified CBD (Epidiolex) is FDA-approved for certain rare epilepsies, including Dravet syndrome and Lennox-Gastaut syndrome. A 2024 systematic review and meta-analysis also found a statistically significant anxiolytic signal for CBD, though the clinical sample remains limited.
• Pain Research: A 2024 systematic review of CBD monotherapy studies concluded that the pain literature is promising but heterogeneous, with trial quality and consistency still limiting confidence in broad analgesic claims.
• Safety: CBD is generally well-tolerated, but a 2023 systematic review found a real signal for liver enzyme elevation and possible drug-induced liver injury in some contexts, particularly with concentrated oral products and polypharmacy settings.

CBG (3,000 mg)

• Evidence Profile: Mostly review-level and preclinical; human evidence remains sparse.
• Pharmacology: CBG is the biosynthetic precursor to several major cannabinoids and appears pharmacologically distinct from both THC and CBD. Review literature describes interactions spanning cannabinoid receptors as well as alpha-2 adrenoceptors and 5-HT1A-related signalling.
• Potential Research Areas: Published reviews discuss possible relevance to neurologic disorders, inflammatory bowel disease, and antibacterial activity, but these are primarily pharmacology-led hypotheses or preclinical findings.
• Caution: CBG is already being sold commercially while the evidence base remains thin, which means claims frequently outrun the science.

Delta-8 THC (6,000 mg)

• Evidence Profile: Pharmacologically relevant, psychoactive, and much less clinically characterised than delta-9 THC.
• Comparative Pharmacology: A 2022 review concluded that delta-8 THC and delta-9 THC have broadly similar pharmacokinetic and pharmacodynamic behaviour. Delta-8 THC is a partial CB1 agonist with cannabimimetic activity in animals and humans, but it appears less potent than delta-9 THC.
• Public Health Literature: A 2023 scoping review found that much of the delta-8 evidence base is still dominated by animal studies, product chemistry, use reports, and public-health concerns rather than strong modern human trials.
• Manufacturing Context: Commercial delta-8 interest is tied to greater stability and easier synthesis relative to naturally scarce plant levels, which is why product-byproduct and lab-testing questions matter.

THCa (1,500 mg)

• Evidence Profile: Important chemically and formulation-wise, but still low on direct human therapeutic evidence.
• What It Is: THCa is the acidic precursor of THC and may represent a very large share of the THC-related content in raw plant material. The key formulation issue is that THCa decarboxylates into THC during heating and can also change over time during storage and processing.
• Psychoactivity: THCa itself does not produce the psychoactive effects associated with THC in humans, but this distinction only holds if the molecule stays in its acidic form and is not substantially decarboxylated.
• Research Status: In vitro and rodent literature suggest anti-inflammatory, immunomodulatory, neuroprotective, and antineoplastic possibilities, but these are not equivalent to established human outcomes.

Delta-9 THC (90 mg)

• Evidence Profile: Strongest human evidence of the psychoactive cannabinoids in our formula, but also the clearest adverse-effect burden.
• Best Supported Uses: NCCIH identifies THC-containing cannabinoid medicines as relevant to chemotherapy-related nausea and vomiting, appetite and weight loss in HIV/AIDS, and some multiple-sclerosis- and pain-related outcomes.
• Pain Evidence: A 2022 systematic review of cannabis-based products for chronic pain found that products with high THC content or roughly comparable THC:CBD ratios may provide short-term pain benefit, but they also increased dizziness, sedation, nausea, and treatment discontinuation due to adverse events.
• Safety: Delta-9 THC carries risks of intoxication, psychiatric effects (anxiety, psychosis), tachycardia, blood-pressure changes, dependency potential, withdrawal symptoms, pregnancy concerns, accidental pediatric exposure, and vape-related lung-injury concerns.

CBN (750 mg)

• Evidence Profile: Weak human evidence; marketing has clearly moved ahead of the data.
• What It Is Often Marketed For: Sleep and sedation. That reputation is widespread, but the clinical support is far thinner than the market suggests.
• Sleep Evidence: The 2021 narrative review on CBN and sleep screened 99 human-study abstracts, reviewed eight full-text articles, and found no clinical trials using validated sleep questionnaires or formal polysomnography that could substantiate strong sleep-promoting claims for CBN.
• Chemical Context: CBN is often discussed in aging or oxidised cannabis chemistry contexts, as THC can degrade toward CBN under certain conditions.

CBC (750 mg)

• Evidence Profile: Emerging, intriguing, and still overwhelmingly preclinical or review-based.
• Pharmacology: A 2024 focused review on CBC argues that it has distinct pharmacodynamics, pharmacokinetics, and receptor behaviour relative to better-known cannabinoids, and highlights antinociceptive, antibacterial, and anti-seizure areas as especially interesting research targets.
• Research Status: Review literature summarising CBC in animal and in vitro work reports anti-inflammatory effects, reduced gut hypermobility, modest rodent analgesic activity, and possible neurobiological or antiproliferative relevance, but these signals are not yet strong evidence for patient-facing claims.

The Evidence Base for Each Terpene

OilWell’s RSO formulas include a defined seven-terpene profile at 5%, designed to complement the cannabinoid blend and enhance the overall experience. Here’s a summary of the evidence for each terpene in our formula:

Limonene

• Evidence Profile: Largely review and preclinical, with useful safety literature.
• Potential Activity: A 2021 review describes limonene as a multifunctional monoterpene with antioxidant, anti-inflammatory, cardioprotective, gastroprotective, immune-modulatory, and other possible activities.
• Safety Note: Limonene oxidation products, especially hydroperoxides, are clinically relevant contact allergens and are important in patch-testing literature.

Myrcene

• Evidence Profile: Mostly preclinical, with very limited human evidence.
• Research Summary: A 2021 review describes anxiolytic, antioxidant, anti-inflammatory, and analgesic properties and discusses possible mechanisms, but explicitly states that human studies are lacking.
• Interpretation Caution: Myrcene is often invoked in consumer language as if it were a proven sedating terpene that explains couch-lock or sleep effects, but this is a stronger claim than the human evidence currently supports.

Caryophyllene (β-Caryophyllene)

• Evidence Profile: Among the most mechanistically interesting terpenes because of direct cannabinoid-system relevance, but still mostly preclinical.
• Why It Stands Out: A 2021 focused review describes beta-caryophyllene as a selective CB2 receptor agonist, which is unusual and makes it especially relevant when discussing cannabis terpenes in pharmacologic terms.
• Research Themes: Anti-inflammatory, immunomodulatory, antioxidant, neuroprotective, gastroprotective, and related actions are repeatedly discussed in the review literature, but human clinical confirmation remains limited.

Pinene

• Evidence Profile: Promising preclinical literature, weak human clinical confirmation.
• Brain-Health Framing: A 2021 review on pinene and linalool as terpene-based medicines for brain health found antioxidant, anti-inflammatory, and neuroprotective signals that justify future study, but it also emphasised that evidence is mostly preclinical and that well-designed clinical trials are lacking.
• Interpretation Caution: Claims that pinene reliably improves memory, sharpens attention, or counterbalances THC-related cognitive effects remain interesting hypotheses rather than settled clinical facts.

Linalool

• Evidence Profile: Similar to pinene: substantial preclinical interest, limited direct clinical confirmation.
• Research Summary: Linalool is repeatedly discussed in relation to stress, mood, and brain-health pharmacology. A 2021 brain-health review found enough preclinical signal to justify continued investigation in neurological and psychiatric contexts.
• Safety Note: As with limonene, oxidised linalool hydroperoxides are recognised allergens in dermatitis literature.

Humulene

• Evidence Profile: Translationally interesting, but still early.
• Scoping-Review Findings: A 2024 scoping review analysed 340 articles and found broad preclinical evidence for anti-inflammatory and other biologic effects, with some rodent work even suggesting cannabimimetic properties via CB1 and adenosine A2a pathways.
• Interpretation Caution: These findings are valuable for hypothesis generation, but they do not yet establish consistent human efficacy across pain, inflammation, or mood outcomes.

Terpinolene

• Evidence Profile: One of the least clinically characterised terpenes in our formula.
• Systematic-Review Findings: A 2021 systematic review screened 2,449 records and included 57 studies, concluding that terpinolene has a range of reported biological effects but that the evidence base is still dominated by in silico, in vitro, and animal studies rather than human trials.
• Interpretation Caution: Even recent cannabis entourage reviews frame terpene benefits as exploratory, not as established compound-specific clinical effects.

The Entourage Effect: More Than the Sum of Its Parts

One of the most compelling aspects of OilWell’s RSO formulas is the potential for the entourage effect, where cannabinoids and terpenes work synergistically to enhance therapeutic outcomes. While the concept of the entourage effect is often discussed in cannabis circles, it’s important to understand what the science actually says.

What Is the Entourage Effect?

The entourage effect refers to the hypothesis that the therapeutic effects of cannabis are enhanced when multiple cannabinoids and terpenes are used together, rather than in isolation. This idea was first proposed by Israeli researcher Raphael Mechoulam in the 1990s and later popularised by neurologist Ethan Russo in a 2011 paper.

The Evidence for the Entourage Effect

• Preclinical Evidence: There is substantial preclinical evidence supporting the entourage effect. For example, a 2018 study published in Frontiers in Plant Science found that whole-plant cannabis extracts were more effective at reducing pain and inflammation in mice than isolated THC or CBD. Another study published in Pharmacology & Therapeutics in 2017 found that terpenes like myrcene and caryophyllene could enhance the analgesic effects of cannabinoids.
• Human Evidence: Human evidence for the entourage effect is more limited but growing. A 2020 study published in Cannabis and Cannabinoid Research found that patients using whole-plant cannabis extracts reported greater symptom relief and fewer side effects than those using isolated cannabinoids. However, the study was observational, and more rigorous clinical trials are needed to confirm these findings.
• Mechanistic Evidence: The entourage effect is supported by mechanistic evidence showing that cannabinoids and terpenes interact with multiple receptor systems in the body. For example, beta-caryophyllene is a selective CB2 receptor agonist, while limonene and linalool interact with serotonin and GABA receptors, respectively. These interactions may enhance the overall therapeutic effect of the cannabis extract.

The Entourage Effect in OilWell’s RSO

OilWell’s RSO formulas are designed to maximise the potential for the entourage effect. Here’s how:

• Multi-Cannabinoid Blend: Our formulas include seven cannabinoids (CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, CBC), each with its own evidence profile and potential therapeutic benefits. This diversity increases the likelihood of synergistic interactions.
• Live Terpenes at 5%: Our formulas include a defined seven-terpene profile (limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene), which may enhance the overall therapeutic effect and improve the sensory experience.
• Full-Spectrum Approach: Unlike isolate-based products, which contain only one cannabinoid, our RSO formulas are full-spectrum, meaning they retain the natural complexity of the cannabis plant. This complexity is believed to be key to the entourage effect.

Limitations and Considerations

While the entourage effect is a compelling concept, it’s important to note that the evidence base is still evolving. Here are some key considerations:

• Limited Human Evidence: Most of the evidence for the entourage effect comes from preclinical studies or observational human studies. More rigorous clinical trials are needed to confirm these findings.
• Individual Variability: The entourage effect may vary from person to person based on factors like genetics, metabolism, and individual biochemistry. What works for one person may not work for another.
• Dosing and Ratios: The optimal cannabinoid and terpene ratios for the entourage effect are not yet well understood. OilWell’s formulas are based on the best available evidence, but individual responses may vary.
• Overstated Claims: Some companies overstate the evidence for the entourage effect, making broad claims that are not yet supported by clinical data. At OilWell, we commit to honest education and avoid overstating the science.

Practical Takeaways for UK Residents

• CBD and Delta-9 THC are the most evidence-developed actives in our formulas, with strong human data supporting their use in specific contexts (e.g., epilepsy, chemotherapy-related nausea, chronic pain).
• Delta-8 THC is a psychoactive cannabinoid with less robust safety and efficacy characterisation than delta-9 THC. It should be treated with caution, particularly by those new to cannabinoids.
• THCa is a non-psychoactive cannabinoid with potential anti-inflammatory and neuroprotective effects, but its interpretation depends on how it is used (raw vs. decarboxylated).
• CBG, CBN, and CBC are scientifically credible but clinically immature compared to CBD and THC. They are included in our formulas for their potential to contribute to the entourage effect.
• Terpenes are biologically active and may enhance the overall therapeutic effect, but compound-specific clinical claims should be made carefully and only where directly supported by evidence.
• The Entourage Effect is a compelling concept with substantial preclinical support, but human evidence remains limited. Our formulas are designed to maximise the potential for synergistic interactions, but individual responses may vary.

Safety and Responsible Use

Safety Considerations for UK Residents

Cannabinoids are generally well-tolerated, but they are not without risks. Here are some key safety considerations for UK residents using OilWell’s RSO:

1. Psychoactivity: Delta-8 THC and delta-9 THC (when decarboxylated from THCa) are psychoactive and can cause impairment. Do not operate vehicles or machinery while under the influence of psychoactive cannabinoids.
2. Drug Interactions: Cannabinoids can interact with other medications, including blood thinners, antidepressants, and sedatives. Consult with a healthcare provider before using OilWell’s RSO if you are taking other medications.
3. Pregnancy and Breastfeeding: The safety of cannabinoids during pregnancy and breastfeeding has not been established. Avoid using OilWell’s RSO if you are pregnant, breastfeeding, or planning to become pregnant.
4. Liver Function: CBD has been associated with liver enzyme elevation in some contexts, particularly with high doses or concentrated oral products. If you have liver disease or are taking medications that affect liver function, consult with a healthcare provider before using OilWell’s RSO.
5. Mental Health: High doses of THC have been associated with anxiety, paranoia, and psychosis in some individuals, particularly those with a personal or family history of mental health conditions. Start with low doses and monitor your response.
6. Allergies: Some individuals may be allergic to cannabis or its components. If you experience allergic symptoms (e.g., rash, itching, swelling), discontinue use and consult a healthcare provider.
7. Pediatric Use: OilWell’s RSO is not intended for use by children. Keep all cannabinoid products out of reach of children.

Responsible Dosing Guidelines

• Start Low and Go Slow: Begin with a low dose (0.25 to 0.5 mL sublingual oil) and assess your response over 2 to 3 hours before increasing. Individual responses vary based on body weight, metabolism, tolerance, and other factors.
• Keep a Journal: Track your dosage, timing, and effects to identify what works best for you. Note any side effects or changes in symptoms.
• Avoid Mixing with Alcohol or Other Substances: Combining cannabinoids with alcohol or other substances can increase the risk of impairment and adverse effects.
• Store Safely: Store OilWell’s RSO in a cool, dark place, away from children and pets. The sublingual oil should be stored at room temperature, while the vape cartridge should be stored upright to prevent leakage.
• Consult a Healthcare Provider: If you have any health concerns or are taking other medications, consult with a healthcare provider before using OilWell’s RSO.

What to Do in Case of Overconsumption

While cannabinoids are generally safe, overconsumption can cause discomfort, particularly with psychoactive cannabinoids like delta-8 THC and delta-9 THC. Here’s what to do if you or someone else experiences overconsumption:

1. Stay Calm: Remember that cannabinoid overconsumption is not life-threatening, but it can be uncomfortable. Stay calm and reassure the person that the effects will pass.
2. Hydrate: Drink water or a non-caffeinated beverage to stay hydrated.
3. Eat Something: Eating a snack can help stabilise blood sugar and reduce feelings of nausea or dizziness.
4. Rest: Lie down in a quiet, comfortable space and try to relax. Close your eyes and focus on deep breathing.
5. Avoid Stimulants: Avoid caffeine, alcohol, or other stimulants, as these can worsen anxiety or discomfort.
6. Seek Medical Attention if Needed: If symptoms are severe (e.g., persistent vomiting, extreme anxiety, rapid heart rate), seek medical attention. In the UK, you can call NHS 111 for non-emergency medical advice or 999 for emergencies.

Frequently Asked Questions (FAQs)

Is OilWell’s RSO Legal in the UK?

Yes, OilWell’s RSO is legal in the UK under current hemp laws. Our products contain less than 0.2% delta-9 THC at the point of sale, which complies with UK regulations for hemp-derived products. However, customers are responsible for verifying local laws and accepting all customs and legal responsibility.

Will OilWell’s RSO Get Me High?

It depends on how you use it:

• Raw (Non-Decarboxylated): If you use the sublingual oil raw, the THCa will remain non-psychoactive, and you will not get high. This option is suitable for daytime use, work, and driving.
• Decarboxylated: If you heat the sublingual oil at 260°F (125°C) for 45-60 minutes, the THCa will convert to delta-9 THC, and the product will become psychoactive. The vape cartridge is also psychoactive, as it automatically decarboxylates THCa at vaping temperature.
• Delta-8 THC: Our formulas also contain delta-8 THC, which is psychoactive but less potent than delta-9 THC. Even in its raw form, the sublingual oil contains delta-8 THC, which may cause mild psychoactive effects in some individuals.

Will OilWell’s RSO Show Up on a Drug Test?

It depends on the type of drug test and how you use the product:

• THCa (Raw): THCa itself is not typically tested for in standard drug tests, which usually screen for delta-9 THC and its metabolites. However, some drug tests may detect THCa, particularly if the sample is heated or processed in a way that converts THCa to THC.
• Delta-8 THC: Delta-8 THC can trigger a positive result on a drug test, as it is chemically similar to delta-9 THC and may produce the same metabolites.
• Delta-9 THC (Decarboxylated): If you decarboxylate the THCa in our sublingual oil or use the vape cartridge, the resulting delta-9 THC will almost certainly trigger a positive result on a drug test.

If you are subject to drug testing, we recommend using the raw (non-decarboxylated) sublingual oil and consulting with your employer or testing provider about the specific substances being tested.

How Do I Decarboxylate OilWell’s RSO?

To decarboxylate the THCa in OilWell’s sublingual oil, follow these steps:

1. Preheat your oven to 260°F (125°C).
2. Transfer the desired amount of oil to an oven-safe glass container (e.g., a small glass jar or ramekin). You can decarboxylate the entire bottle or just a portion.
3. Place the container in the preheated oven and bake for 45-60 minutes. This will convert the THCa to delta-9 THC.
4. Remove the container from the oven and allow it to cool. The oil is now decarboxylated and ready to use.
5. Store the decarboxylated oil in a cool, dark place. It can be used sublingually, added to food, or applied topically.

Important Note: Decarboxylation will make the oil psychoactive. Do not operate vehicles or machinery while under the influence of psychoactive cannabinoids.

Can I Use OilWell’s RSO Topically?

Yes, OilWell’s sublingual oil can be applied topically, though it is designed primarily for sublingual use. The organic MCT oil base makes it suitable for topical application, and the multi-cannabinoid formula may provide anti-inflammatory and analgesic benefits for conditions like arthritis, muscle soreness, and skin irritation.

To use topically, apply a small amount of the oil to the affected area and massage it into the skin. You can also mix it with a carrier oil or lotion to improve absorption. For best results, use the raw (non-decarboxylated) oil to avoid psychoactive effects.

How Long Does OilWell’s RSO Last?

• Sublingual Oil: The sublingual oil has a shelf life of 1-2 years when stored properly in a cool, dark place. The graduated dropper allows for precise dosing, and the 30 mL bottle provides approximately 40-60 doses, depending on serving size.
• Vape Cartridge: The vape cartridge has a shelf life of 1 year when stored upright in a cool, dark place. The 1-gram cartridge provides approximately 100-200 puffs, depending on inhalation technique.

Can I Travel with OilWell’s RSO?

We do not recommend travelling with OilWell’s RSO, particularly across international borders. While our products are legal under UK hemp laws, laws vary by country, and cannabinoid products may be confiscated or result in legal consequences if you are travelling internationally.

If you must travel with OilWell’s RSO, we recommend:

• Keeping the product in its original packaging with the Certificate of Analysis (COA) and receipt.
• Checking the laws of your destination country before travelling.
• Declaring the product to customs if required.
• Keeping the product in your carry-on luggage (never in checked baggage).

Can I Use OilWell’s RSO with Other Medications?

Cannabinoids can interact with other medications, including blood thinners, antidepressants, sedatives, and medications that affect liver function. If you are taking other medications, consult with a healthcare provider before using OilWell’s RSO.

Here are some common drug interactions to be aware of:

• Blood Thinners (e.g., Warfarin): CBD can inhibit the metabolism of warfarin, increasing the risk of bleeding. If you are taking warfarin or other blood thinners, monitor your INR levels closely and consult with a healthcare provider.
• Antidepressants (e.g., SSRIs, SNRIs): Cannabinoids can interact with antidepressants, potentially increasing the risk of side effects like drowsiness, dizziness, or serotonin syndrome.
• Sedatives (e.g., Benzodiazepines, Opioids): Cannabinoids can enhance the sedative effects of these medications, increasing the risk of drowsiness, respiratory depression, or overdose.
• Liver-Metabolised Medications: CBD can inhibit liver enzymes (e.g., CYP3A4, CYP2C19) that metabolise many medications, potentially increasing their levels in the bloodstream and the risk of side effects.

Can I Give OilWell’s RSO to My Pet?

OilWell’s RSO is formulated for human use and is not intended for pets. However, we do offer a CBD golden paste recipe for pets on our About Us page, which you can make at home using pet-safe ingredients.

If you are considering using cannabinoids for your pet, consult with a veterinarian first. Pets metabolise cannabinoids differently than humans, and THC can be toxic to animals, particularly dogs.

How Does OilWell’s RSO Compare to UK Medical Cannabis?

OilWell’s RSO offers several advantages over typical UK medical cannabis products:

1. Accessibility: No prescription is required. Anyone aged 21 or older can purchase OilWell’s RSO, making it accessible to those who cannot obtain a medical cannabis prescription.
2. Cost: OilWell’s RSO is significantly more affordable than private medical cannabis prescriptions, which can cost hundreds or thousands of pounds per month.
3. Cannabinoid Diversity: Our formulas include seven cannabinoids (CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, CBC) and seven terpenes, offering a broader therapeutic profile than many UK medical cannabis products, which are often THC-dominant or CBD-dominant.
4. THCa Preservation: Our sublingual oil includes THCa as a separate ingredient, allowing customers to choose between non-psychoactive and psychoactive use.
5. Lab Testing: Our products undergo full-panel third-party testing for potency, terpenes, pesticides, heavy metals, residual solvents, and microbial contaminants, with Certificates of Analysis (COAs) available on request.

However, it’s important to note that OilWell’s RSO is not a substitute for medical cannabis prescribed by a healthcare provider. If you have a medical condition that may benefit from cannabis-based medicines, consult with a healthcare provider to explore all available options.

Can I Use OilWell’s RSO for Cancer?

OilWell’s RSO is not a cure for cancer, and we do not make any claims that it can treat, cure, or prevent cancer. While preclinical studies have shown that cannabinoids like THC and CBD can induce apoptosis (programmed cell death) and inhibit tumour growth in certain cancer cell lines and animal models, these findings have not translated into proven human cancer cures.

If you are considering using OilWell’s RSO as part of a cancer treatment plan, we strongly recommend consulting with an oncologist or healthcare provider. Cannabinoids may offer supportive benefits for symptoms like nausea, pain, and appetite loss, but they should not replace conventional cancer treatments like surgery, radiation, chemotherapy, or immunotherapy.

How Do I Store OilWell’s RSO?

• Sublingual Oil: Store at room temperature in a cool, dark place, away from direct sunlight and heat. The graduated dropper should be kept clean and dry to prevent contamination.
• Vape Cartridge: Store upright in a cool, dark place, away from direct sunlight and heat. Avoid exposing the cartridge to extreme temperatures, as this can affect the viscosity of the oil and the performance of the cartridge.

Can I Use OilWell’s RSO While Pregnant or Breastfeeding?

The safety of cannabinoids during pregnancy and breastfeeding has not been established. We strongly recommend avoiding OilWell’s RSO if you are pregnant, breastfeeding, or planning to become pregnant. Consult with a healthcare provider for personalised advice.

What Is the Best Way to Take OilWell’s RSO?

The best way to take OilWell’s RSO depends on your needs and lifestyle:

• Sublingual Oil: Ideal for sustained relief, precise dosing, and daytime non-psychoactive use (when used raw). Place the desired dose under your tongue and hold it for 60-90 seconds before swallowing to maximise sublingual absorption.
• Vape Cartridge: Ideal for fast relief, portability, and discretion. Inhale 1-2 puffs and hold the vapour in your lungs for a few seconds before exhaling. The effects are felt within 1-2 minutes.

How Do I Know If OilWell’s RSO Is Right for Me?

OilWell’s RSO may be right for you if:

• You are seeking a natural, multi-cannabinoid approach to managing conditions like chronic pain, insomnia, anxiety, or chemotherapy-related nausea.
• You want the flexibility to choose between non-psychoactive and psychoactive use.
• You value transparency, lab testing, and evidence-based formulations.
• You are looking for a legal, accessible alternative to UK medical cannabis.
• You are open to exploring the potential benefits of the entourage effect.

However, OilWell’s RSO may not be right for you if:

• You are pregnant, breastfeeding, or planning to become pregnant.
• You are subject to drug testing and cannot risk a positive result.
• You have a personal or family history of mental health conditions (e.g., psychosis, schizophrenia) that may be exacerbated by THC.
• You are taking medications that may interact with cannabinoids (e.g., blood thinners, antidepressants, sedatives).
• You are not comfortable with the psychoactive effects of THC (unless you use the raw sublingual oil).

How Can I Learn More About OilWell’s RSO?

For more information about OilWell’s RSO, visit our RSO Guide Page. This page includes detailed product information, competitive analysis, protocols, and ordering details.

You can also contact us directly with any questions:

• Phone: +1 (832) 416-2816 (international calls)
• Email: [email protected]
• Website: https://oilwellcbd.com/
• Instagram: @oilwellcbd

The Future of RSO in the UK

The UK’s relationship with cannabis is evolving. From the legalisation of medical cannabis in 2018 to the growing interest in hemp-derived products, the conversation around cannabis therapeutics is gaining momentum. Yet, for many UK residents, access to high-quality, full-spectrum cannabis extracts like RSO remains limited.

OilWell Cannabis is committed to changing that. Our RSO formulas are designed to be accessible, transparent, and evidence-based, offering UK residents a legal and effective alternative to traditional RSO and expensive medical cannabis products. By publishing our complete formulas and providing honest, science-backed education, we empower UK residents to make informed decisions about their health.

As the UK continues to explore the potential of cannabis-based medicines, we believe that products like OilWell’s RSO will play an increasingly important role. Whether you’re seeking relief from chronic pain, insomnia, anxiety, or chemotherapy-related symptoms, our RSO formulas are designed to meet you where you are — with science, transparency, and a commitment to accessibility.

Final Thoughts: Why OilWell’s RSO Stands Apart in the UK

In a market flooded with CBD isolates, THC-dominant products, and overhyped wellness claims, OilWell’s RSO stands apart for three key reasons:

1. Science: Our formulas are anchored in peer-reviewed research, with evidence profiles for every cannabinoid and terpene. We don’t make claims that aren’t supported by science, and we commit to honest education about what the evidence actually says.
2. Transparency: We publish our complete formulas, provide third-party lab testing, and offer Certificates of Analysis (COAs) for every product. No other RSO company in the UK is as transparent as OilWell.
3. Accessibility: Our THCa legal framework makes our products legal under UK hemp laws, and our international shipping ensures that UK residents can access the same high-quality RSO as our customers in the U.S. No medical card is required, and our open-source formulas allow those who can’t afford our products to make their own.

OilWell’s RSO is more than a product — it’s a promise. A promise to honour the legacy of Rick Simpson while evolving his vision for the modern era. A promise to provide UK residents with a legal, safe, and effective alternative to traditional RSO and expensive medical cannabis. And a promise to always put science, transparency, and accessibility first.

Whether you’re new to cannabis therapeutics or a seasoned user, we invite you to explore the potential of OilWell’s RSO. Start low, go slow, and discover what our multi-cannabinoid, terpene-rich formulas can do for you.

Ready to try OilWell’s RSO?

• Buy RSO Sublingual Oil
• Buy RSO Vape Cartridge
• Learn More About RSO

Have questions?

• Phone: +1 (832) 416-2816 (international calls)
• Email: [email protected]
• Instagram: @oilwellcbd

Together, let’s redefine what RSO can be — for the UK and beyond.